Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors

Alessia Mongelli; Veronica Barbi; Michela Gottardi Zamperla; Sandra Atlante; Luana Forleo; Marialisa Nesta; Massimo Massetti; Alfredo Pontecorvi; Simona Nanni; Antonella Farsetti; Oronzo Catalano; Maurizio Bussotti; Laura Adelaide Dalla Vecchia; Tiziana Bachetti; Fabio Martelli; Maria Teresa La Rovere; Carlo Gaetano

Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors

2021

The SARS-CoV-2 infection determines the COVID-19 syndrome characterized, in the worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokine release, and immunosuppression. This condition has led to the death of about 2.15% of the total infected world population so far. Among survivors, the presence of the so-called persistent post-COVID-19 syndrome (PPCS) is a common finding. In COVID-19 survivors, PPCS presents one or more symptoms: fatigue, dyspnea, memory loss, sleep disorders, and difficulty concentrating. In this study, a cohort of 117 COVID-19 survivors (post-COVID-19) and 144 non-infected volunteers (COVID-19-free) was analyzed using pyrosequencing of defined CpG islands previously identified as suitable for biological age determination. The results show a consistent biological age increase in the post-COVID-19 population, determining a DeltaAge acceleration of 10.45 ± 7.29 years (+5.25 years above the range of normality) compared with 3.68 ± 8.17 years for the COVID-19-free population (p < 0.0001). A significant telomere shortening parallels this finding in the post-COVID-19 cohort compared with COVID-19-free subjects (p < 0.0001). Additionally, ACE2 expression was decreased in post-COVID-19 patients, compared with the COVID-19-free population, while DPP-4 did not change. In light of these observations, we hypothesize that some epigenetic alterations are associated with the post-COVID-19 condition, particularly in younger patients (< 60 years).

اظهر المزيد [+]